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Perspectives
Cell Death Response to DNA Damage
Jean Y. J. Wang*
Department of Cellular & Molecular Medicine, University of California, San Diego, CA
The cell death response to DNA damage is discussed in this Perspectives piece with cancer as the backdrop 
because DNA damaging agents (DDA†) are widely used to treat cancer. From decades of clinical results, 
we learn that DDA have cured some cancers but their toxicity is temporary in most cancers due to 
emergence of DDA-resistant cancer cells. Investigation of DDA-activated genes, proteins, and pathways, 
known collectively as the DNA damage response (DDR), has uncovered the inner workings of DDR 
that protect the genome to sustain life. Paradoxically, however, DDR can also activate death. Current 
knowledge on DDA-activated death and hypotheses for how DDR may determine when and where to 
execute death are discussed. Given that cancer cells suffer from DDR defects, which account for their 
initial sensitivity to DDA, future therapeutic development may exploit those cancer-specific DDR defects 
to selectively create death-inducing DNA lesions, without using DDA, to kill DDA-resistant cancers.
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INTRODUCTION
DNA is the blueprint of life. When that blueprint is 
irrevocably damaged, life ceases. To stay alive, therefore, 
requires a continuous effort to protect that blueprint. By 
its chemical nature, DNA is not inert but highly reactive 
to elements that are prevalent in the macro- and the mi-
cro- environment, e.g., oxygen free radicals or UV light 
[1-3]. Hence, living organisms are endowed with a so-
phisticated toolbox to monitor and repair damages to their 
DNA. In the evolutionarily conserved parts of this tool-
box, we have found proteins, enzymes, and gene products 
that detect DNA lesions, assemble the appropriate repair 
machineries, and coordinate a concerted effort from vir-
tually every biological process to achieve the goal of sur-
vival, that is, to sustain life. Collectively, these proteins, 
enzymes and gene products constitute a biological net-
work known as the DNA Damage Response (DDR) [4]. 
Since DNA is constantly damaged, DDR is constantly 
deployed. DDR defects are detrimental, for they either 
cause outright lethality or mutation accumulation to drive 
diseases, most notably, cancer [4-8].
The oncology practice of applying DNA damaging 
agents (DDA) to treat cancer began empirically in the 
early 20th century soon after physicists discovered X-rays 
[9,10]. To date, radiation and DNA-damaging drugs have 
remained the mainstay modality of cancer therapy. The 
clinical observation that DDA can kill cancer cells sup-
ports the idea that DNA damage is detrimental. However, 
we have now come to appreciate the reason for how on-
cologists can empirically determine a dose of DDA that 
kills cancer cells without destroying the body, and that is 
because cancer cells tend to suffer repair defects and are 
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therefore more likely to be killed by DDA [11]. After a 
century of advancements and successes in curing a signif-
icant number of childhood cancers [12], DDA have failed 
to cure the majority of adult cancers because their toxicity 
is temporary. After the initial destruction of cancer cells 
by DDA, some malignant cells that survive the insult can 
resume proliferation and pass the know-how on surviving 
DDA to their progenies, and thereby neutralizing the tox-
ic effect of radiation and chemotherapy on the recurring 
cancers. The conclusions that DDR defects drive cancer 
development and that DDR-defective cells are hypersen-
sitive to DDA are irrefutable [11]; however, the consis-
tent failure of DDA to cure adult cancer suggests that we 
may not have fully comprehended the capacity of DDR to 
sustain life. In the laboratories, biologists have observed 
cells to adapt to damage by resuming proliferation de-
spite the presence of an irreversible lesion in their DNA 
[13-17]. Given that survival is perhaps the strongest se-
lective pressure, it makes sense for DDR to have evolved 
strategies to sustain life even when DNA damage persists. 
The fact that we have not been very successful in either 
preventing or reversing the resistance of recurring can-
cers to DDA exposes the gaps in our knowledge on the 
life-sustaining capacity of DDR.
Paradoxically, this life-sustaining DDR also has the 
capability to actively kill cells [18-22]. In our body, the 
genetic blueprint assembled by the fusion of a sperm and 
an egg is repeatedly copied, i.e., replicated, during devel-
opment and throughout adult life such that each human 
DNA blueprint is collectively held by tens of trillions of 
cells. This multiplicity of the blueprint affords multicellu-
lar organisms with the luxury to actively kill off excess or 
damaged cells [23], including those with damaged DNA 
[18-22]. The cell-killing programs are embedded in the 
DNA blueprint in that the genomes of multicellular or-
ganisms encode proteins and enzymes that when activat-
ed can kill cells [23,24]. Although the death programs are 
available to every cell of an organism, they are not always 
activated by DNA damage. For example, in the nematode 
Caenorhabditis elegans, DNA damage activates death in 
germ cells but not somatic cells [25]; and in the develop-
ing nervous system of the mouse, DNA damage activates 
death in neuroblasts but not differentiated neurons [26]. 
In other words, the death option in DDR is not universal – 
not all living organisms choose to die in response to DNA 
damage, and not all cell types in an organism choose to 
die, either. Obviously, the death programs could not have 
evolved without the co-evolution of suppressors to keep 
the killing-machines under wrap [27]. Generally speak-
ing, the death option in DDR is more prevalently acti-
vated in cells that are either destined to die or are readily 
replaceable, such as those in highly regenerative tissues 
[28]. In this context, active elimination of damaged cells 
is not only affordable but may also be beneficial to the 
survival of the organisms [23]. On the whole, however, it 
is important to emphasize that the death option in DDR is 
suppressed in most mature tissues of our body.
In this Perspectives piece, I offer what I consider to 
be well-established death programs that can be activated 
by DNA damage, and discuss the current knowledge on 
how cancer cells may suppress these programs to survive 
radiation and chemotherapy.
TOPICS
MODALITIES OF DNA DAMAGE-INDUCED 
CELL DEATH
Passive vs Active Death to DNA Damage
The death response to DNA damage falls into two cat-
egories: death-from-failure-to-repair vs death-by-choice. 
The death-from-failure-to-repair is passive; an unintend-
ed consequence brought on by detrimental DNA-lesions 
that interfere with the copying (replication), reading 
(transcription), and proper functioning (condensation 
and segregation) of the blueprint. The death-by-choice, 
in contrast, is an active response, an action brought on by 
the inner workings of the DDR [22]. Although the pas-
sive vs the active death responses are easy to discern on 
paper, they can be difficult to distinguish experimentally 
because the death-by-choice is not, and obviously cannot, 
be immediately activated upon the detection of any DNA 
lesion. Rather, the active death is a delayed response in 
DDR and coordinated with the status of DNA repair [20]. 
Further confounding the experimental categorization of 
passive vs active death is the finding that death-from-re-
pair-failure, rather than an unintended consequence, may 
involve necroptosis, which is a killing-machine activated 
by inflammatory cytokines, oxidative stress, and other 
metabolic triggers [29]. Given these findings, it would be 
prudent, for the time being, to consider none of the DNA 
damage-induced death response to be entirely passive.
Coordination between DNA Repair and Death in 
DDR
A widely accepted theory posits that DDA activates 
the death-programs only when DNA-lesions become ir-
reparable. Underlying this theory is the assumption that 
DDR has the ability to distinguish between a reparable 
DNA-lesion from one that is irreparable [20,21]. Al-
though DDR can distinguish between different types of 
DNA lesions to stimulate the proper repairs of those le-
sions [20,30,31], there is no evidence that the lesion-de-
tectors can distinguish between those that are reparable 
from those that are irreparable. In the absence of evidence 
for the existence of detectors that can recognize irrepara-
ble DNA-lesions, we must consider alternative hypoth-
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eses for how DNA repair may be coordinated with the 
execution of cell death.
Since the killing-machines must not be activated im-
mediately upon the detection of a DNA lesion, because 
lesions do occur under normal physiological conditions, 
there should exist in DDR mechanisms to delay death 
execution. One such delay mechanism is the built-in re-
quirement for transcription induction and new protein 
synthesis, which take time, to activate cell death [20,24]. 
The requirement for new gene expression to execute 
death not only provides a safeguard but could also allow 
for DDR to activate counter-measures to further con-
trol the death machines. It is conceivable that DNA le-
sion-detectors may simultaneously activate DNA-repair, 
a death-program, and suppressors of that death program 
(Figure 1). By activating both death and death-suppres-
sors, it would become possible to set a time window for 
DNA repair (Figure 1). In this scenario, it is the combi-
nation of repair-efficiency and the death suppressor lifes-
pan that determines the timing of death execution. In this 
scheme, if DNA-lesions are repaired within the lifespan 
of death-suppressors, cells do not die (Figure 1). How-
ever, if DNA-lesions are not repaired within the lifespan 
of death-suppressors, death is executed (Figure 1). In 
cells where DDR does not induce death-suppressors, or 
in cells where the lifespan of DDR-induced death-sup-
pressors is very short, we would observe a rapid onset of 
death following exposure to a low dose of DDA, such as 
the case of embryonic neuroblasts [26,32]. On the other 
hand, in cells with constitutively expressed death-sup-
pressors such as mature neurons [33], death can be pre-
vented despite persistence of DNA-lesions. This idea that 
DDR can set a window-for-repair, either short or infinite, 
forgoes the need for detectors of irreparable lesions and 
negates the requirement for DDR to make judgments 
on the progress of repair [20]. Rather, in this model, the 
killing-machines can be pre-set, by the inner workings 
of DDR in conjunction with the context of a given cell 
type, for activation after a given window-of-time. While 
plausible, this theory of a time-dependent regulation of 
DNA damage-induced death is still pending experimental 
validation.
Figure 1. Regulation of Death Execution in DNA Damage Response: a Window-for-Repair Hypothesis. In DNA 
damage response (DDR), the detection of DNA-lesion (red star) must not immediately activate cell death because DNA 
lesions are continuously generated under physiological conditions. Instead, DNA damage-induced cell death is a de-
layed response, observed after hours and even days following exposure to DNA damaging agents (DDA) [20,22]. This 
delay in executing DDA-induced death is often explained by the theory that death is activated only when the DNA-le-
sions are irreparable. Since there is no evidence for any cellular mechanisms that can distinguish between reparable 
vs irreparable DNA-lesions [21], I propose an alternative hypothesis for how DDR can determine when and where 
to execute cell death. In this hypothesis, DNA damage simultaneously activates DNA repair, death, and death-sup-
pressors (upper panel). Successful repair eliminates the damage and terminates DDR to prevent death, whereas 
death-suppressors also prevent death execution. By setting the lifespan of death-suppressors, this design of parallel 
pathway activations pre-sets a window of time for repair (lower panel). During this window of time, DNA damage cannot 
activate death because of the death suppressors. However, after the decay of death-suppressors, death is activated if 
the damage is not repaired (lower panel). Of course, if the damaged is repaired before the decay of death-suppressors, 
death is avoided because DDR is terminated. Cells with a short window-for-repair would be very sensitive to DDA-in-
duced death. On the other hand, with an infinite window-for-repair, cells would become resistant to DDA-induced death.
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with the life-sustaining goal of DDR, activated p53 in-
duces the transcription of hundreds of genes to promote 
survival by: (a) stimulating DNA repair, (b) installing 
cell cycle checkpoints, and (c) reprograming metabolism 
[43,44]. However, the activated p53 also induces the tran-
scription of pro-apoptotic genes to produce PUMA and 
NOXA proteins [44-47]. PUMA (product of the human 
BBC3 gene) and NOXA (product of the human PMAIP1 
gene) activate apoptosis by breaking down the anti-apop-
tosis defense mechanism to cause mitochondrial release 
of cytochrome C, which activates the apoptosome to 
stimulate caspases [24,39]. In mice, knockout of Tp53, 
or Bbc3 plus Pmaip1, abolished DDA-induced apoptosis 
in neuroblasts, thymocytes, and other cell types in which 
apoptosis is an option of DDR [48-50]. Therefore, the 
pathway from p53 to PUMA and NOXA is essential to 
DDA-induced apoptosis (Figure 2).
Futile Repair Activates Necroptosis
Necroptosis is a genetic program that, when ac-
tivated, causes a necrotic form of cell death [29]. Ne-
crotic death, or necrosis, describes the morphology of 
cell swelling, membrane rupture and the spilling of cell 
content, which are easily distinguishable from the mor-
Activation of Apoptosis by DNA Damaging Agents 
(DDA)
The evolutionarily conserved program of apoptosis, 
when activated, causes cells to condense and fragment 
their DNA and other content into apoptotic bodies that are 
recognized and engulfed by neighboring cells or profes-
sional phagocytes [34]. During embryonic development, 
the apoptosis program is deployed to eliminate cells in 
order to form digits [35]. In the development of immune 
tolerance, apoptosis is deployed to eliminate self-reactive 
lymphocytes [36]. Upon infection, apoptosis can be de-
ployed to eliminate infected cells to prevent the spread of 
pathogens [37]. Biologists have found several different 
routes to executing the apoptotic form of death [38]. In 
DDR, activation of apoptosis requires mitochondrial re-
lease of cytochrome C to stimulate caspases (Figure 2), 
which cleave hundreds of proteins to cause the distinct 
features of apoptotic death [39].
Without a doubt, the most important player that en-
ables the apoptosis option in DDR is the transcription fac-
tor p53, encoded by the human TP53 gene, with orthologs 
in other vertebrate species. The p53 protein is a member 
of the rapid-response-team activated by the master kinas-
es (ATM, ATR, DKN-PK) in DDR [40-42]. In keeping 
Figure 2. DNA Damage-Induced Cell Death Modalities and Their Suppression. The DDR master kinases, ATM, 
ATR, DNAPK, that are activated by DNA damage, phosphorylate a transcription factor p53 itself, encoded by the Tp53 
tumor suppressor gene, and its inhibitors (MDM2) to stabilize and activate p53 [40]. The activated p53 stimulates the 
expression of hundreds of genes, including those encoding PUMA and NOXA, two pro-apoptotic proteins [44]. PUMA 
and NOXA stimulate apoptosis by causing the release of mitochondrial cytochrome C (Cyt. C), which then stimulates 
the assembly of apoptosome to activate apoptosis [24]. Tp53 is one of the most frequently mutated genes in cancers, 
and the loss of p53 disconnects DNA damage to the activation of apoptosis. Futile repair describes the process where 
a continuous and non-productive repair progress depletes ATP and NAD to cause oxidative stress, which activates the 
necrosome to stimulate necroptosis [29,52]. The necrosome can be silenced by the suppression of RIPK3 expression 
in cancers [51]. In actively proliferating cells, DNA lesions can interfere with DNA synthesis by stalling the replication 
forks. If cells with incompletely replicated DNA break through G2-arrest to enter mitosis, the condensation of partially 
replicated sister-chromatids will shatter the DNA to cause mitotic catastrophe [57]. DNA damage-induced growth arrest 
can sustain life by blocking DNA replication and mitosis to avoid mitotic catastrophe.
Wang: Cell death response to DNA damage 775
minal differentiation [20,21]. The fact that it is possible 
for oncologists to empirically determine a DDA dosage 
that kills cancer cells but does not destroy the brain or 
the heart is because terminally differentiated neurons and 
cardiac muscle cells are more resistant to DDA [21,60]. 
The therapeutic doses of DDA do kill off normal prolifer-
ative cells in the bone marrow, the intestines, or the hair 
follicles, but these tissues contain sufficient numbers of 
quiescent stem cells for regeneration after cessation of 
DDA treatment.
The common characteristic among quiescent, senes-
cent and terminally differentiated cells is the withdrawal 
from DNA replication. In quiescent cells, the withdrawal 
is reversible, that is, quiescent cells retain the capacity 
to initiate DNA replication when the conditions become 
favorable. In senescent cells, the withdrawal from DNA 
replication is irreversible and no longer stimulated by 
growth factors [61]. Because non-proliferative cells do 
not replicate DNA or enter mitosis, they are less likely 
to die by mitotic catastrophe (Figure 2). Terminally dif-
ferentiated neurons and muscle cells also express higher 
levels of apoptosis suppressors [33,62]. It is of interest to 
note that necroptosis can still be activated by oxidative 
stress in aging neurons or cardiac muscle cells [63,64], 
and may account for neural and cardiac toxicity associat-
ed with chemotherapy [65,66].
Tp53 Mutation in Cancer
The human Tp53 is one of the most frequently mu-
tated genes in cancers; as a result, p53-driven apoptotic 
response to DNA damage is lost in cancer cells. While 
p53 induces PUMA and NOXA to activate apoptosis, it 
is important to point out that p53 also inhibits DNA rep-
lication. According to a meta-analysis of published data 
on p53-target genes, CDKN1A is the most consistently, or 
universally, induced when p53 becomes activated [44]. 
CDKN1A encodes the p21CIP1 protein that inhibits Cdk/
Cyclin to enforce G1-arrest, promote senescence and re-
duce death [67]. The fact that the p53-CDKN1A pathway 
is also a part of DDR shows that p53-activation alone is 
not sufficient to determine whether a damaged cell will 
undergo growth arrest or apoptosis. Despite decades of 
research and numerous hypotheses [22,68], we have not 
yet arrived at a consensus on how the conflict between 
the pro-arrest and the pro-apoptosis functions of p53 is 
resolved in DDR. Obviously, resolution of this conflict is 
irrelevant to cancer development because Tp53 is mutat-
ed in most cancer cells.
PROLIFERATION DESPITE PERSISTENT 
DAMAGE
Besides the suppression of cell death, recurring can-
cer cells may also activate strategies to continue prolif-
phological features of apoptosis [29]. Pathogens or blunt 
force injuries can rupture the cell membrane to cause 
necrosis. However, necrotic death can also result from 
activation of necroptosis, or from the opening of the mi-
tochondrial permeability pore (PTP) [38]. The execution 
of necroptosis is stimulated by the necrosome, consist-
ing of the RIPK1 and RPIK3 protein kinases, acting at 
the plasma membrane and in the mitochondria [29,38]. 
DNA damaging agents (DDA) can cause necrotic death 
that requires RIPK1 and RIPK3 [22,29,51]. Whereas the 
master kinases of DDR (ATM, ATR, DNA-PK) directly 
phosphorylate and activate p53 [40-42], there is no ev-
idence as yet for a direct link between the DDR master 
kinases and the RIPKs. Instead, activation of necroptosis 
by DDA may result from futile-repair, which describes 
a continuous but non-productive repair process that can 
lead to the unintended depletion of ATP and NAD [52]. 
In other words, activation of necroptosis is an unintended 
consequence of repair failure (Figure 2).
Replication Failure and Mitotic Catastrophe
DNA replication is essential to cell proliferation, tis-
sue regeneration and tumor growth. To ensure the com-
plete and faithful replication of cellular DNA, DDR has 
a cadre of redundant and robust mechanisms to repair le-
sions ahead of replication and to re-start replication that 
is stalled by DNA-lesions [53,54]. In proliferative cells, 
upon detection of DNA damage, the DDR master kinas-
es phosphorylate key proteins to prevent the initiation of 
DNA replication in G1-cells that have not yet commit-
ted to DNA synthesis, and this DDR action is referred 
to as the G1-checkpoint or G1-arrest [20,55,56]. In cells 
that have committed to but not yet completed replication, 
DDR master kinases phosphorylate other key proteins to 
prevent the onset of mitosis [20,55,56]. This G2-arrest 
reduces the risk of mitotic catastrophe, where chromo-
somes are shattered when incompletely replicated sister 
chromatids become condensed [57]. In the event where 
DDR fails to enforce G2-arrest while DNA replication 
forks are stalled, mitotic death would ensue [58,59]. In 
other words, the normal process of mitotic chromatin 
condensation can cause unintended death when DNA le-
sions prevent the completion of DNA replication (Figure 
2).
SUPPRESSION OF DNA DAMAGE-
INDUCED CELL DEATH
Quiescence, Senescence, or Terminal 
Differentiation
Generally speaking, DDA are more likely to kill pro-
liferative than non-proliferative cells, including those in 
quiescence, senescence, or those that have undergone ter-
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with a unique arrangement of these DNA [72] and non-
unique but efficient repair machines [73], contribute to 
the ability of D. radiodurans to reassemble their genet-
ic blueprint even after extensive breakage. One of the 
phenotypes of malignant cancer cells is aneuploidy, with 
losses and gains in chromosome copy numbers [74]. The 
lessons from D. radiodurans suggest that chromosome 
copy number gains may promote cancer resistance to ra-
diation therapy. The idea that polyploidy can contribute 
to acquired radio-resistance in cancer is supported by ex-
perimental evidence [75,76]; however, the mechanisms 
that drive polyploidy-dependent resistance to radiation 
therapy have remained to be elucidated.
CONCLUSIONS AND OUTLOOKS
Our knowledge on the cell death response to DNA 
damage has advanced at a fast pace over the past few 
decades. Considering that pace, the current gaps in our 
knowledge on the life-sustaining capacity of DDR will 
certainly be filled in due course. The important question 
to ponder, at this time, is how we may apply the knowl-
edge on DNA damage-induced cell death to efficiently 
and irreversibly kill off cancer cells.
Outlook-1: The field will continue to search for 
death-suppressors that are activated in recurring cancer 
cells to block DDA-induced death. Relevant to this line 
of investigation is the fact that execution of apoptosis 
or programmed necrosis requires leakage of killer-pro-
teins or calcium ions from the outer or the inner mito-
chondrial membrane, respectively [38]. Although Tp53 
is often mutated in cancer cells, PUMA, NOXA, and 
other mitochondrial killer-proteins are seldom mutated. 
Furthermore, cancer cells are dependent on mitochon-
drial metabolites to support nucleotide biosynthesis and 
proliferation [77]. Because tumor growth requires mi-
tochondria, and because mitochondria execute death, it 
is reasonable to assume that mitochondrial protection is 
enhanced in DDA-resistant cancer cells. The best-known 
suppressors of mitochondria-dependent apoptosis are the 
BCL2-family of mitochondrial outer membrane protec-
tors [78]. Drugs have been developed to neutralize the 
protective functions of BCL2-family members; however, 
disabling this family of death-suppressors has had limited 
success in reversing DDA-resistance [79]. Protection of 
the mitochondrial outer membrane, unfortunately, does 
not prevent mitochondria permeability transition (MPT), 
where the opening of the PTP (permeability transition 
pore) in the inner mitochondrial membrane causes mas-
sive leakage of calcium and other metabolites to kill cells 
[38]. After four decades of investigation, the molecular 
identify of PTP has remained mysterious [80], thus hin-
dering the search for suppressors of MPT. While new in-
sights on mitochondrial protection may reveal additional 
eration despite persistent DNA damage. Several such 
strategies discovered in unicellular organisms are worth 
considerations.
Adaptation to Cell Cycle Checkpoints
Cell cycle checkpoints describe DDR-mechanisms 
that prevent the initiation of DNA replication (G1-check-
point) or the entry into mitosis (G2-checkpoint) [69]. 
The checkpoint mechanisms are reversible so that cells 
can resume proliferation after lesions are repaired. Ge-
netic experiments conducted in the model eukaryotic 
yeast cells have found that checkpoints are also revers-
ible even when DNA lesions are not repaired. By induc-
ing a double-stranded break (DSB) to activate cell cycle 
checkpoints in yeast cells that cannot repair DSB, it was 
found that the repair-defective yeast cells broke through 
the checkpoints and resumed DNA replication despite 
the DSB in their DNA [13]. This process of overcoming 
checkpoints despite lesion-persistence is described as the 
adaption to DNA damage. In human cancer cells, Tp53 
mutation weakens the checkpoints and can thus promote 
adaptation. Orthologs of Tp53 are not found in yeast, 
but the yeast genes required for adaptation are conserved 
through evolution [13]. Hence, DDA-resistant cancer 
cells could, beyond Tp53 mutation, additionally activate 
the evolutionarily conserved adaption genes to resume 
proliferation even when DNA lesions are not repaired.
Lesion-Bypass DNA Replication
In cells that have committed to DNA replication, 
DDA activates the S-phase checkpoint that inhibits the 
firing of replication origins, but only temporarily [53]. 
Thus, the commitment to replicating DNA is accompa-
nied with ways to rapidly adapt to DNA lesions. One 
such way is to activate DNA polymerases that can syn-
thesize DNA across lesions [70]. These lesion-bypass 
polymerases are conserved in prokaryotic and eukary-
otic cells [70]. Although lesion-bypass DNA synthesis 
causes mutations, the evolutionary conservation of these 
enzymes suggests that error-prone replication is prefera-
ble to no replication. The human genome encodes over a 
dozen of lesion-bypass DNA polymerases, which cancer 
cells can explore to replicate damaged DNA. Such muta-
genic DNA synthesis may further drive the emergence of 
DDA-resistant progenies.
Polyploidy
The bacteria Deinococcus radiodurans, named for 
extreme resistance to radiation, can withstand radiation 
doses that shatter their DNA into hundreds of fragments. 
By sequencing its genome, biologists found D. radiodu-
rans to contain between 4 to 10 genome equivalent of 
sequences [71]. This redundancy in gene copies, together 
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cause DDA-resistant cancer cells may adopt mechanisms 
that protect neurons and cardiac muscles, there may exist 
a limit on how far we can push for mitochondria-depen-
dent cell killing in cancer therapy.
Outlook-2: As an alternative to enforcing mito-
chondria-dependent cell killing, cancer researchers are 
exploiting the DDR defects in cancer cells to induce 
cancer-specific DNA-lesions that can activate mitochon-
dria-independent death. Since the cell cycle checkpoints 
are weakened and the repair machines are compromised 
by DDR-defects in cancer, it is plausible to devise strat-
egies, without using DDA, to selectively create death-in-
ducing DNA lesions only in cancer cells [82]. As an 
example, cancer cells with defects in homologous re-
combination (HR) repair, due to mutations of BRCA1 or 
BRCA2, are hypersensitive to DDA [83]. Interestingly, 
BRCA1- or BRCA2-mutant cells are also sensitive to in-
hibitors of PARP (poly-ADP-ribose polymerase), which 
is a DNA-repair enzyme [84]. In patients with HR-de-
fective cancers, PARP inhibitors have delayed cancer 
progression but they have not improved overall surviv-
al [85]. Nevertheless, the success with PARP inhibitors 
demonstrates that it is possible to design enzyme inhibi-
tors to selectively cause DNA damage in repair-defective 
cancer cells [86]. Moving forward, it is likely that other 
enzyme inhibitors will be developed to irreversibly block 
the replication forks in DDR-defective cancer cells. By 
combining replication blockade with induction of chro-
matin condensation, it is possible to kill cancer cells 
through mitotic catastrophe without the need for apopto-
sis or necroptosis. Judging from the recent flurry of inves-
tigations on replication stress [87-89], we look forward 
to new insights on how to selectively activate replication 
stress and chromosome fragmentation in DDR-defective 
and DDA-resistant cancer cells.
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